Brief: Australian Clinical Labs Says Reviewing Healius' Target's Statement
05/05/2023 02:33
May 5 (Reuters) - Australian Clinical Labs Ltd ACL.AX :
* REVIEWING & CONSIDERING INFORMATION CONTAINED IN HEALIUS
TARGET’S STATEMENT WITH ITS ADVISERS
* ACL'S OFFER FOR HEALIUS IS OPEN FOR ACCEPTANCE UNTIL
7.00PM
(SYDNEY TIME) ON 29 SEPT
* NOTES HEALIUS IDENTIFIES NUMBER OF CONDITIONS OF OFFER
THAT IT
CONSIDERS ARE NOT LIKELY TO BE SATISFIED
Source text for Eikon: ID:nASX6126vn
Further company coverage: ACL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Australian Clinical Labs
See all newsBrief: Australian Clinical Labs Appoints Deloitte As Auditor
Australia's Optiscan rises after imaging more than 80 cases in ACL study
Australian Clinical Labs falls to over two-week low on trading ex-dividend
Australian Clinical Labs at 6-month high on upbeat full-year results, guidance
Brief: Australian Clinical Labs Says It Expects FY27 Revenue Of A$745-765 Million